Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Stéphane, Jouveshomme"'
Autor:
Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, Sylvie Friard, Christos Chouaid, Boris Duchemann, Etienne Giroux-Leprieur, Laurent Taillade, Ludovic Doucet, Marina Nguenang, Stéphane Jouveshomme, Marie Wislez, Jean Tredaniel, Jacques Cadranel
Publikováno v:
ERJ Open Research, Vol 4, Iss 2 (2018)
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aime
Externí odkaz:
https://doaj.org/article/56562b3a065e4d9c99bfdfbd2cc1f82d
Autor:
Hélène Beaussier, Nassim Mohamedi, David M. Smadja, Olivier Sanchez, Isabelle Lazareth, Lina Khider, Marc Zins, Joseph Emmerich, Alexandra Yannoutsos, Laure Fournier, Gilles Chatelier, Cédric Bruel, Guillaume Goudot, Stéphane Jouveshomme, Benjamin Planquette, Jean Luc Diehl, Tristan Mirault, Jean-Jacques Mourad, Marie de Torcy, Nicolas Gendron, Emmanuel Messas, Alice Le Berre, Guy Meyer, Pascal Priollet
Publikováno v:
Thrombosis Research
Thrombosis Research, 2021, 197, pp.94-99. ⟨10.1016/j.thromres.2020.11.001⟩
Thrombosis Research, 2021, 197, pp.94-99. ⟨10.1016/j.thromres.2020.11.001⟩
Introduction Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. Previous studies reported pulmonary embolism (PE) in severe COVID-19 patients. Aim of the study was to estimate the prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8558d35135c3e99e15873e3dfb75a5c7
https://hal.science/hal-03493066/document
https://hal.science/hal-03493066/document
Autor:
Gilles Hayem, Stéphane Jouveshomme, Jean-Jacques Mourad, Thomas Huet, Gilles Chatellier, Hélène Beaussier
Publikováno v:
The Lancet Rheumatology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0abc65c53d8bb3066f063fc14fe402
https://pubmed.ncbi.nlm.nih.gov/32838321
https://pubmed.ncbi.nlm.nih.gov/32838321
Autor:
Gilles Hayem, Gilles Chatellier, Hélène Beaussier, Olivier Voisin, Yvonnick Bézie, Stéphane Jouveshomme, Sophie Laplanche, Joseph Emmerich, Gaëlle Dauriat, Thomas Huet, Emmanuelle Sacco, Jean-Jacques Mourad, Sergio Salmeron, Isabelle Lazareth, Alice Le Berre, Jean Marc Naccache, Jérôme Le Pavec
Publikováno v:
The Lancet Rheumatology
Summary Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagoni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dffec85365ce2365d363b12de362503
Autor:
Pierre Laurent-Puig, Véronique Giraudet, Alice Guyard, Anne Tallet, Françoise Le Pimpec-Barthes, Etienne Giroux-Leprieur, William Digan, Catherine Julié, Bastien Rance, Hélène Blons, Jean Pastre, Antoine Legras, Alain Cazier, Véronique Duchatelle, Nicolas Pécuchet, Stéphane Jouveshomme, Laure Gibault, Elizabeth Fabre, Marc Barritault
Publikováno v:
The Journal of Molecular Diagnostics. 20:550-564
Theranostic assays are based on single-gene testing, but the ability of next-generation sequencing (NGS) to interrogate numerous genetic alterations will progressively replace single-gene assays. Although NGS was evaluated to screen for theranostic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d519bf203a65848b34c4b8b601aceaf
https://doi.org/10.1016/j.jmoldx.2018.04.002
https://doi.org/10.1016/j.jmoldx.2018.04.002
Publikováno v:
Annales de biologie clinique. 75:19-27
Tuberculosis is one of the main etiologies to evoke in the context of lymphocyte pleurisy. However, diagnosis is difficult and is based on mycobacteriology that is not enough sensitive and time-consuming, or on histology that requires invasive biopsy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b00e1a1ad65e31e546655d84bd54c72
https://doi.org/10.1684/abc.2016.1201
https://doi.org/10.1684/abc.2016.1201
Autor:
Jennifer Corny, Stéphane Jouveshomme, Adrien Costantini, Marie Wislez, Vincent Fallet, Sylvie Friard, Sophie Renet, Christos Chouaid, Jean Trédaniel, Laurent Taillade, Ludovic Doucet, Jacques Cadranel, Etienne Giroux-Leprieur, Marina Nguenang, Boris Duchemann
Publikováno v:
Lung Cancer.
Background: Nivo is the gold standard for second line treatment of advanced NSCLC. Hyper-progression (HP) is a form of early progression observed during treatment by immune checkpoint inhibitors and usually fatal which has been poorly evaluated. Aim:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e560563b3dbe3a0972313d021dde865e
https://doi.org/10.1183/13993003.congress-2018.pa2808
https://doi.org/10.1183/13993003.congress-2018.pa2808
Autor:
Antoine, Legras, Marc, Barritault, Anne, Tallet, Elizabeth, Fabre, Alice, Guyard, Bastien, Rance, William, Digan, Nicolas, Pecuchet, Etienne, Giroux-Leprieur, Catherine, Julie, Stéphane, Jouveshomme, Véronique, Duchatelle, Véronique, Giraudet, Laure, Gibault, Alain, Cazier, Jean, Pastre, Françoise, Le Pimpec-Barthes, Pierre, Laurent-Puig, Hélène, Blons
Publikováno v:
The Journal of molecular diagnostics : JMD. 20(4)
Theranostic assays are based on single-gene testing, but the ability of next-generation sequencing (NGS) to interrogate numerous genetic alterations will progressively replace single-gene assays. Although NGS was evaluated to screen for theranostic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cee21afa6ebcd8021d619c7166b73304
https://pubmed.ncbi.nlm.nih.gov/29787863
https://pubmed.ncbi.nlm.nih.gov/29787863
Autor:
Jennifer Corny, Adrien Costantini, Christos Chouaid, Jean Trédaniel, Sophie Renet, Sylvie Friard, Laurent Taillade, Stéphane Jouveshomme, Marina Nguenang, Vincent Fallet, Ludovic Doucet, Jacques Cadranel, Marie Wislez, Etienne Giroux-Leprieur, Boris Duchemann
Publikováno v:
ERJ Open Research
ERJ Open Research, Vol 4, Iss 2 (2018)
ERJ Open Research, Vol 4, Iss 2 (2018)
Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c23f7f444674bf89aa4b233e89d4841
https://pubmed.ncbi.nlm.nih.gov/29692997
https://pubmed.ncbi.nlm.nih.gov/29692997